In the October issue of Chem, Piel and co-workers revealed that the biosynthetic potential for the incorporation of pharmacophoric a-keto-b-amino acids in ribosomal peptides is distributed across members of a wealth of bacterial genera. This unusual post-translational modification can potentially be applied to drug discovery anddesign, particularly of protease inhibitors.